FVB/N-Tg(S100A8-NRAS*G12D)1Bop/Orl

Status	Available to order
EMMA ID	EM:11135
Citation information	RRID:IMSR_EM:11135 Research Resource Identifiers (RRID) are persistent unique ID numbers assigned to help researchers cite key resources (e.g. antibodies, model organisms and software projects) in the biomedical literature to improve transparency and reproducibility in research. See https://www.rrids.org/ for more information.
International strain name	FVB/N-Tg(S100A8-NRAS*G12D)1Bop/Orl
Alternative name	MRP8NRASD12
Strain type	Transgenic Strains
Allele/Transgene symbol	Tg(S100A8-NRAS*G12D)1Bop
Gene/Transgene symbol	Tg(S100A8-NRAS*G12D)1Bop

Information from provider

Provider	Scott Kogan
Provider affiliation	Laboratory Medicine, University of California San Francisco
Genetic information	NRAS-G12D
Phenotypic information	Homozygous: Unknown Heterozygous: Puffy cheeks due to infections.
Breeding history	The strain has been bred since 1998.
References	The PEBP2betaMYH11 fusion created by Inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia.;Kogan S C, Lagasse E, Atwater S, Bae S C, Weissman I, Ito Y, Bishop J M, ;1998;Proceedings of the National Academy of Sciences of the United States of America;95;11863-8; 9751756 BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia.;Omidvar Nader, Kogan Scott, Beurlet Stephanie, le Pogam Carole, Janin Anne, West Robert, Noguera Maria-Elena, Reboul Murielle, Soulie Annie, Leboeuf Christophe, Setterblad Niclas, Felsher Dean, Lagasse Eric, Mohamedali Azim, Thomas N Shaun B, Fenaux Pierre, Fontenay Michaela, Pla Marika, Mufti Ghulam J, Weissman Irving, Chomienne Christine, Padua Rose Ann, ;2007;Cancer research;67;11657-67; 18089795
Homozygous fertile	not known
Homozygous viable	not known
Homozygous matings required	no
Immunocompromised	yes

Information from EMMA

Archiving centre	CNRS-TAAM – Typing and Archiving of Animal Models, Orléans, France
Animals used for archiving	heterozygous FVB/N males

Literature references

The PEBP2betaMYH11 fusion created by Inv(16)(p13;q22) in myeloid leukemia impairs neutrophil maturation and contributes to granulocytic dysplasia.;Kogan S C, Lagasse E, Atwater S, Bae S C, Weissman I, Ito Y, Bishop J M, ;1998;Proceedings of the National Academy of Sciences of the United States of America;95;11863-8; 9751756
BCL-2 and mutant NRAS interact physically and functionally in a mouse model of progressive myelodysplasia.;Omidvar Nader, Kogan Scott, Beurlet Stephanie, le Pogam Carole, Janin Anne, West Robert, Noguera Maria-Elena, Reboul Murielle, Soulie Annie, Leboeuf Christophe, Setterblad Niclas, Felsher Dean, Lagasse Eric, Mohamedali Azim, Thomas N Shaun B, Fenaux Pierre, Fontenay Michaela, Pla Marika, Mufti Ghulam J, Weissman Irving, Chomienne Christine, Padua Rose Ann, ;2007;Cancer research;67;11657-67; 18089795

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Frozen sperm. Delivered in 4 weeks (after paperwork in place). €1740^*
Rederivation of mice from frozen stock, delivery time available upon request . €3880^*

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

^* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
Distribution of this strain is subject to a provider MTA. Both signing of the MTA and submission of the online EMMA Mutant Request Form are required before material can be shipped.

EMMA conditions
Legally binding conditions for the transfer

Right strain for your research?

The information provided on this page is, to the best of EMMA’s knowledge, based on data supplied by the original provider. End users are responsible for reviewing these details and for validating the strain and its suitability for their experimental use.
Not found what you were looking for? Search here for other strains available from EMMA.